Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 5,92 € (-74,13%). La mediana è 5,92 € (-74,13%).
| Acquista |
3 |
| Mantieni |
5 |
| Vendi |
1 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Treace Medical beats Q2 forecasts; shares jump about 24% premarket
Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Altro su de.investing.com
Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly
Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Altro su de.investing.com
Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand
Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Altro su de.investing.com
Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making
Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Altro su de.investing.com
Treace Medical Concepts beats Q2 forecasts and shares rise after hours
Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 42,6 Mln | 0,44% |
| Utile lordo | 33,86 Mln | 0,07% |
| Utile netto | -11,09 Mln | 20,07% |
| EBITDA | -9,7 Mln | 6,52% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 264,93 Mln € |
Numero di azioni | 65,56 Mln |
Massimo/minimo a 52 settimane | 4,95 € - 1,06 € |
| Dividendi | No |
Beta | 1,56 |
Rapporto P/E | -5,16 |
Rapporto PEG | 0,49 |
Rapporto P/B | 4,72 |
Rapporto P/S | 1,43 |
Profilo aziendale
Treace Medical Concepts, Inc., una società di dispositivi medici ortopedici, si occupa della progettazione, della produzione e della commercializzazione di dispositivi medici per chirurghi del piede e della caviglia negli Stati Uniti. Offre la procedura Lapiplasty, che consente ai chirurghi podologici di trattare tutte e tre le dimensioni dell'alluce valgo, offrendo ai pazienti un miglioramento estetico e medico. La società fornisce inoltre il sistema di precisione Lapiplasty Mini-Incision. Inoltre, offre prodotti per procedure chirurgiche accessorie, tra cui osteotomie di Akin, osteotomie di Weil, stabilizzazione intercuneiforme, artrodesi della articolazione tarsometatarsale laterale e prelievo di osso autologo, nonché per l'artrodesi MTP. Treace Medical Concepts, Inc. è stata fondata nel 2013 ed ha sede a Ponte Vedra Beach, in Florida.
| Nome | Treace Medical Concepts |
| CEO | John T. Treace |
| Sede centrale | Ponte Vedra,
fl Stati Uniti |
| Sito web | |
| Settore | Beni voluttuari |
| Industria | Beni durevoli per la casa |
| Quotazione in borsa | 23/04/2021 |
| Dipendenti | 450 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | TMCI |